Narrow-Moat Alcon Has Defensive Characteristics, Refractive Is Most Exposed To Recession Risks

Business Strategy and Outlook

As a global leader in eyecare, Alcon provides products and equipment for various vision conditions such as refractive errors, cataracts, and advanced vitreoretinal problems. The firm is the second-biggest player in contact lenses and has a robust portfolio in liquid eyecare solutions for allergies and dry eye. Despite a strong market position, Alcon remains in turnaround mode following years of underinvestment as a Novartis subsidiary. The company has committed significant capital to the turnaround program with greater sales and marketing spending, and capital expenditures that are expected to total over $1.5 billion over the next three years. Looking past expected lumpiness of near-term results, management’s turnaround efforts will largely pay off and there is a positive view of the outlook on the core business.

Alcon’s strategy centers on growth in premium product lines, implementing cost-saving initiatives to drive margin expansion, and capitalizing on secular long-term growth in global eyecare. Specifically, the firm has identified three main areas of growth for the business: advanced intraocular lenses (PanOptix, Vivity), premium daily contact lenses (Total1, Precision1), and liquid eyecare (Systane, Pataday). Within each of these markets, Alcon has a premium product that should allow for near-term above-market growth. Alcon’s leading position in phacoemulsification for cataract surgery, with a 50% market share, helps pull in demand for standard intraocular lenses, or IOL, from bundling, and Alcon now holds a greater-than-50% share in IOLs, as well. The firm recently launched a value-priced phaco system that should generate share gains in emerging markets, which have been slower to adapt phaco because of higher up-front costs. Alcon’s standard IOL business is expected to grow about in line with market, and the introduction of PanOptix to the U.S. market should enable above-market growth for the advanced lens portfolio. PanOptix is the first trifocal in the U.S., and this lens has benefited from its first-mover advantage, with the product achieving 75% share of advanced IOL sales in the U.S. and Japan.

Financial Strength

Alcon’s financial strength is satisfactory. The firm took on $3.5 billion of debt in early 2019 related to the spin-off from Novartis, and the company ended 2021 with a moderate degree of leverage (debt/EBITDA ratio of 2.6). Interest coverage is a moderate concern to us in the near term given that interest expenses are projected to exceed operating income in 2021. This is partly due to the refinancing of $2 billion of debt in 2019, which resulted in higher interest expense. Still, this also lengthened the maturity of the debt, giving Alcon improved longer-term financial stability. Given current assumptions about operating income growth over the coming years, interest coverage is not anticipated to be a long-term concern, and the coverage ratio is expected to surpass 10 times by the back half of the 10-year forecast period. In early 2019, about a month before Alcon once again became a public firm, the company acquired fluid-based intraocular lens maker Powervision for $285 million. The firm is likely to make a few similarly sized tuck-in acquisitions over the next few years, in the range of $50 million to $500 million, such as the $475 million acquisition of Ivantis in November 2021. With Alcon’s total market cap at around $35 billion, this acquisition range is meaningful but not necessarily material to the overall business, and the company has enough free cash flow to pursue acquisitions of this size. Positive free cash flow to the firm is projected throughout the 10-year explicit forecast period, indicating the firm has ample financial flexibility.

Bulls Say’s

Alcon stands to benefit from several secular trends in eyecare: an increasing prevalence of myopia, demand for better eyecare from a growing middle-class in emerging markets, and growth driven by an aging population.
As a stand-alone public firm, Alcon will have the necessary financial flexibility to make investments for the longer term, and patient investors could be well rewarded.
Alcon’s product pipeline (fluid-based intraocular lenses, accommodating contact lenses, Systane line expansion) will help the firm maintain and expand its position as the global leader in eyecare.

Company Profile

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

(Source: MorningStar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.